Indomethacin-induced small intestinal injury is ameliorated by cilostazol, a specific PDE-3 inhibitor

References

• Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172–8.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992;33:1204–8.
   PubMed Web of Science ®Google Scholar
• Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I. Effect of longterm misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study. Gut 1995;37:195–8.
   PubMedGoogle Scholar
• Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008;43:270–6.
   PubMed Web of Science ®Google Scholar
• Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77:761–7.
   PubMed Web of Science ®Google Scholar
• Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333–41.
   PubMed Web of Science ®Google Scholar
• Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999;40:517–24.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008;57:181–7.
   PubMed Web of Science ®Google Scholar
• Miura S, Suematsu M, Tanaka S, Nagata H, Houzawa S, Suzuki M, Microcirculatory disturbance in indomethacin-induced intestinal ulcer. Am J Physiol 1991;261:G213–19.
   PubMedGoogle Scholar
• Morise Z, Komatsu S, Fuseler JW, Granger DN, Perry M, Issekutz AC, ICAM-1 and P-selectin expression in a model of NSAID-induced gastropathy. Am J Physiol 1998;274:G246–52.
   PubMedGoogle Scholar
• Ryningen A, Jensen BO, Holmsen H. Role of autocrine stimulation on the effects of cyclic AMP on protein and lipid phosphorylation in collagen-activated and thrombin-activated platelets. Eur J Biochem 1999;260:87–96.
   PubMedGoogle Scholar
• Moore KL, Patel KD, Bruehl RE, Li F, Johnson DA, Lichenstein HS, P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol 1995;128:661–71.
   PubMed Web of Science ®Google Scholar
• Salter JW, Krieglstein CF, Issekutz AC, Granger DN. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol 2001;281:G1432–9.
   PubMed Web of Science ®Google Scholar
• Inoue T, Tsuzuki Y, Matsuzaki K, Matsunaga H, Miyazaki J, Hokari R, Blockade of PSGL-1 attenuates CD14+ monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice. J Leukoc Biol 2005;77:287–95.
   PubMedGoogle Scholar
• Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003;92:26M–36M.
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:1237–43.
   PubMed Web of Science ®Google Scholar
• Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 2000;108:136–46.
   PubMedGoogle Scholar
• Schmidt W, Tinelli M, Secchi A, Gebhard MM, Martin E, Schmidt H. Influence of amrinone on intestinal villus blood flow during endotoxemia. J Crit Care 2000;15:97–102.
   PubMedGoogle Scholar
• Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: Phosphodiesterase inhibitors. Br J Clin Pharmacol 2011;72:6334–46.
   Google Scholar
• Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 2001;101:445–53.
   PubMedGoogle Scholar
• Ito H, Miyakoda G, Mori T. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets 2004;15:293–301.
   PubMed Web of Science ®Google Scholar
• Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Ouchi M, Ito Y. Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 2006;26:522–6.
   PubMed Web of Science ®Google Scholar
• Higashiyama M, Hokari R, Matsunaga H, Takebayashi K, Watanabe C, Komoto S, P-selectin-dependent monocyte recruitment through platelet interaction in intestinal microvessels of LPS-treated mice. Microcirculation 2008;15:441–50.
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Hokari R, Higashiyama M, Kurihara C, Okada Y, Watanabe C, Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. Am J Physiol Gastrointest Liver Physiol 2009;297:G1077–84.
   PubMedGoogle Scholar
• Ohba R, Otaka M, Odashima M, Jin M, Komatsu K, Konishi N, Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats. J Gastroenterol 2006;41:34–40.
   PubMedGoogle Scholar
• Odashima M, Otaka M, Ohba R, Jin M, Wada I, Horikawa Y, Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats. Dig Dis Sci 2007;52:1355–9.
   PubMed Web of Science ®Google Scholar
• Gao L, Wang F, Wang B, Gong B, Zhang J, Zhang X, Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther 2006;318:53–8.
   PubMed Web of Science ®Google Scholar
• Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008;57:1583–91.
   PubMed Web of Science ®Google Scholar
• Wang F, Li M, Cheng L, Zhang T, Hu J, Cao M, Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci 2008;83:828–35.
   PubMedGoogle Scholar
• Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008;7:494–9.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008;47:330–6.
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–68.
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004;11:600–2.
   PubMed Web of Science ®Google Scholar
• Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl 2005;6:13–19.
   PubMedGoogle Scholar
• Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 1970;101:478–83.
   PubMedGoogle Scholar
• Wu CC, Lu YZ, Wu LL, Yu LC. Role of myosin light chain kinase in intestinal epithelial barrier defects in a rat model of bowel obstruction. BMC Gastroenterol 2010;10:39.
   PubMedGoogle Scholar
• Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998;124:1385–94.
   PubMedGoogle Scholar
• Ishikawa M, Cooper D, Russell J, Salter JW, Zhang JH, Nanda A, Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 2003;34:1777–82.
   PubMed Web of Science ®Google Scholar
• Tailor A, Granger DN. Hypercholesterolemia promotes P-selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arterioscler Thromb Vasc Biol 2003;23:675–80.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Kusaka G, Yamaguchi N, Sekizuka E, Nakadate H, Minamitani H, Platelet and leukocyte adhesion in the microvasculature at the cerebral surface immediately after subarachnoid hemorrhage. Neurosurgery 2009;64:546–53.
   PubMedGoogle Scholar
• Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010;67:499–511.
   PubMed Web of Science ®Google Scholar
• Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 2004;68:119–25.
   PubMed Web of Science ®Google Scholar
• Iwama D, Miyamoto K, Miyahara S, Tamura H, Tsujikawa A, Yamashiro K, Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. J Thromb Haemost 2007;5:818–25.
   PubMedGoogle Scholar
• McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746–56.
   PubMed Web of Science ®Google Scholar
• Rivera-Nieves J, Burcin TL, Olson TS, Morris MA, McDuffie M, Cominelli F, Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med 2006;203:907–17.
   PubMedGoogle Scholar
• Tailor A, Cooper D, Granger DN. Platelet-vessel wall interactions in the microcirculation. Microcirculation 2005;12:275–85.
   PubMed Web of Science ®Google Scholar
• Iwai T, Ichikawa T, Goso Y, Ikezawa T, Saegusa Y, Okayasu I, Effects of indomethacin on the rat small intestinal mucosa: immunohistochemical and biochemical studies using anti-mucin monoclonal antibodies. J Gastroenterol 2009;44:277–84.
   PubMedGoogle Scholar
• Satoh H, Hara T, Murakawa D, Matsuura M, Takata K. Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats. Dig Dis Sci 2010;55:1264–71.
   PubMedGoogle Scholar
• Hokari R, Lee H, Crawley SC, Yang SC, Gum JR Jr, Miura S, Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am J Physiol Gastrointest Liver Physiol 2005;289:G949–59.
   PubMedGoogle Scholar
• Kunikata T, Araki H, Takeeda M, Kato S, Takeuchi K. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes. J Physiol Paris 2001;95:157–63.
   PubMedGoogle Scholar
• Takeuchi K, Kita K, Hayashi S, Aihara E. Regulatory mechanism of duodenal bicarbonate secretion: roles of endogenous prostaglandins and nitric oxide. Pharmacol Ther 2011;130:59–70.
   PubMedGoogle Scholar
• Hayashi M, Kita K, Ohashi Y, Aihara E, Takeuchi K. Phosphodiesterase isozymes involved in regulation of HCO3- secretion in isolated mouse duodenum in vitro. Biochem Pharmacol 2007;74:1507–13.
   PubMedGoogle Scholar
• Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710–13.
   PubMed Web of Science ®Google Scholar